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Abstract
The linking genotype to phenotype is the fundamental aim of modern genetics. We focus
on study of links between gene expression data and phenotype data through integrative
analysis. In this work, we propose three approaches.
1) The inherent complexity of phenotypes makes high-throughput phenotype profil-
ing a very difficult and laborious process. We propose a method of automated multi-
dimensional profiling which uses gene expression similarity. Large-scale analysis of more
than 500 gene expression datasets show that our method can provide robust profiling that
reveals different phenotypic aspects of samples. This profiling technique is also capable
of interpolation and extrapolation beyond the phenotype information given in training
data. As such, it can be used in many applications, including facilitating experimental
design and detecting confounding factors.
2) Phenotype association analysis problems are complicated by small sample size and
high dimensionality. Consequently, phenotype-associated gene subsets obtained from
training data are very sensitive to selection of training samples, and the constructed sam-
ple phenotype classifiers tend to have poor generalization properties. To eliminate these
obstacles, we propose a novel approach that generates sequences of increasingly discrim-
inative gene cluster combinations. Our experiments on both simulated and real datasets
ix
show that the resulting cluster combinations are robust to perturbation in training sam-
ples and have good sample phenotype classification performance.
3) Many complex phenotypes, such as cancer, are the product of not only gene expres-
sion, but also gene interaction. We propose an integrative approach to find gene network
modules that activate under different phenotype conditions and apply this approach to
the study of cancer. Using our method on multiple cancer gene expression datasets, we
discovered cancer subtype-specific network modules, as well as the ways in which these
modules coordinate. In particular, we detected a breast-cancer specific tumor suppressor
network module with a hub gene, PDGFRL, which may play an important role in this
module.
x
Chapter 1
Introduction
1.1 Integrative analysis of gene expression and phenotype
association
With the advancement of the high-throughput genotyping technologies, large amounts of
genotype data have been accumulated in recent years. Such data include gene expres-
sion, single nucleotide polymorphism, copy number variation, DNA mythelation, histone
acetylation, alternative splicing, and proteomics. Since the fundamental problem in mor-
den genetics is the linking of genotype to phenotype. we are particularly interested in
the associations between gene expression and phenotype in this dissertation.
1.2 Gene expression and phenotype data
With the completion of the Human Genome Project, biology research is entering the post
genome era. Although biologists have collected a vast amount of DNA sequence data,
the details that would explain how these sequences function still remain largely unknown.
Genomes of even the simplest organisms are very complex. Key questions still confront
1
biologists, including 1) the functional roles of different genes and the cellular processes
in which they participate; 2) how genes are regulated, how genes and gene products
interact, and how to identify interaction networks; and, finally, 3) how gene expression
levels differ in various cell types and states, as well as how gene expression is changed by
various disease pathologies and their treatments. Biology used to be a data-poor science.
Nowadays, however, many of these questions can be addressed with the advent of more
advanced techniques, such as gene expression. Therefore, investigators are now able to
transform vast amounts of biological information into useful data.
This makes it possible to study gene function globally, and a new field, functional
genomics, emerges. Specifically, functional genomics refers to the development and ap-
plication of global (genome-wide or system-wide) experimental approaches to assess gene
function by making use of the information and reagents provided by structural genomics.
Gene function may be divided into gene expression, which refers to the process of tran-
scribing a gene’s DNA sequence into the RNA that serves as a template for protein
production, and the level of gene expression, which indicates how active a gene is in cer-
tain tissues, at certain times, or under certain experimental conditions. Therefore, the
monitoring of gene function can provide an overall picture of the genes being studied, in-
cluding their expression level and the activities of the corresponding protein under certain
conditions. To accomplish this, functional genomics provides techniques characterized by
high-throughput or large-scale experimental methodologies combined with statistical and
computational analysis of the results.
Among the several methods that have been developed to understand the behavior
of genes, microarray technology is particularly important. It is used to simultaneously
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monitor the expression levels of genes by several orders of magnitude, and many steps
are involved in this technology. First, complementary DNA (cDNA) molecules or oligos
are printed onto slides as spots. Then, two kinds of dye-labeled samples, i.e., sample and
control, are hybridized. Finally, the hybridization is scanned and stored as images (Figure
1.1). Using a suitable image processing algorithm, these images are then quantified into a
set of expression values representing the intensity of spots. Usually, the dye intensity may
be biased by factors, such as physical property, experimental variability in probe coupling
and processing procedures, and scanner settings. To minimize the undesirable effects
caused by this biased dye intensity, normalization is done to balance dye intensities and
make expression value comparable across experiments. Here the term comparable means
that the difference of any measured expression value of a gene between two experiments
should reflect the difference of its true expression levels.
A phenotype is any observable characteristic of an organism. Phenotypes result from
the activities of an organism’s genes as well as the influence of environmental factors
and possible interactions between the two. Phenotypes are often described in natural
languages in the literature. They can sometimes be measured as continuous or categorical
values. While it has thus far been very difficult to automatically extract phenotype
information from the literature, the Unified Medical Language System (UMLS) has been
developed in recent years to provide facilities for natural language processing. As such,
UMLS is a compendium of many controlled vocabularies in the biomedical sciences. It
provides a mapping structure among these vocabularies and thus gives researchers the
ability to translate among the various terminology systems. It is also a comprehensive
thesaurus and ontology of biomedical concepts and consists of the following components:
3
Figure 1.1 A diagram illustrating how gene expression is obtained from microarray
experiments. Figure obtained from http://www.mun.ca
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1) a Metathesaurus, the core database of the UMLS, which is a collection of concepts
and terms from the various controlled vocabularies and their relationships; 2) a Semantic
Network which is a set of categories and relationships that are used to classify and relate
the entries in the Metathesaurus; and 3) a SPECIALIST Lexicon which is a database of
lexicographic information for use in natural language processing. A number of supporting
software tools are also provided for this system.
1.3 Integrative analysis of gene-phenotype
association
In recent years, the accumulation of gene expression data has been a rapid process. For
example, the two largest public gene expression repositories, Gene Expression Ominibus
(GEO) and Array Express, already contain more than 500,000 samples, measuring genome
wide gene expression levels of various organisms under various phenotypic conditions.
Basically, these gene expression data repositories contain two types of information:
gene expression and sample phenotype information. Expression information based on
microarrays are measured in continuous values. On the other hand, sample phenotype
information is often described in natural language, or it can be manually structured and
recorded into a database. We develop methods of integrative analysis which combine
these two types of information obtained from different experimental sources, therefore
enhancing confidence and providing a better understanding of the association between
genotype and phenotype.
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1.4 Summary of our work
As indicated above, we propose three approaches for the above analysis. 1) We propose
the concept and a method of Automated Multi-dimensional Phenotypic Profiling by using
genotype information as a bridge. 2) We propose a method that can robustly search for
combination of gene sets that provides true discrimination and good prediction of sample
phenotype classes. 3) We propose an integrative approach to characterize disease-specific
pathways and their coordination using gene coexpression network analysis. The first work
primarily focus on phenotype prediction. Both the second and third work above involve
studying different aspects of gene phenotype associations. The second work focus on
selecting phenotype associated combinations of gene sets, while the third work particularly
focus on genetic interaction mechanism that is associated to phenotype difference.
1.4.1 Automated multi-dimensional phenotype profiling
Phenotypes are complex and difficult to quantify in a high-throughput fashion. The lack
of comprehensive phenotype data can prevent or distort genotype-phenotype mapping. In
Chapter 2 we describe PhenoProfiler, a novel computational method that enables in sili-
con phenotype profiling. Drawing on the principle that similar gene expression patterns
are likely to be associated with similar phenotype patterns, PhenoProfiler supplements
the missing quantitative phenotype information for a given microarray dataset based on
other well-characterized microarray datasets.
We applied our method to 587 human microarray datasets covering more than 14,000
samples, and confirmed that the predicted phenotype profiles are highly consistent with
6
true phenotype descriptions. PhenoProfiler offers several unique capabilities: (1) au-
tomated, multi-dimensional phenotype profiling, facilitating the analysis and treatment
design of complex diseases; (2) the extrapolation of phenotype profiles beyond provided
classes; and (3) the detection of confounding phenotype factors that would otherwise
bias biological inferences. Finally, as no direct comparisons are made between gene ex-
pression values from different datasets, the method can utilize the entire body of cross-
platform microarray data. This work has produced a compendium of novel phenotype
profiles for the NCBI GEO datasets, which can facilitate an unbiased understanding of
transcriptome-phenome mapping. By increasing the variaty and the quality of pheno-
types to be profiled, the continued accumulation of microarray data will further increase
the power of PhenoProfiler.
1.4.2 Stable refinement of discriminative gene clusters
Gene expression data are often used to identify the phenotype associated genes that are
differentially expressed between samples of two phenotype classes. On the other hand,
since microarray datasets contain only a small number of samples and a large number of
genes, it is usually desirable to identify small gene subsets with distinct patterns between
sample phenotype classes. Such gene subsets are highly discriminative in phenotype clas-
sification because of their tightly coupling features. Unfortunately, gene subsets obtained
from training data are often very sensitive to the selection of training samples, and the
classifiers constructed from such gene subsets usually tend to have poor generalization
properties on the test samples as a result of the overfitting problem.
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In Chapter 3, we propose a novel approach [XZZ08] to correct these problems by
combining supervised and unsupervised learning techniques to generate increasingly dis-
criminative gene cluster combinations in an iterative manner. Compared with existing
approaches, our experiments on both simulated and real datasets show that our method
can produce a series of gene cluster combinations that are robust to training sample per-
turbation and have good sample phenotype classification performance. This backward
approach for refining a series of highly discriminative gene cluster combinations for the
purpose of sample phenotype classification has proven to be very consistent and stable
when applied to various types of training data. In addition, these combinations can be
further used to study the underlying genetic interactions that lead to phenotype differ-
ence, and extended to integrate gene clusters obtained from multiple datasets consisting of
similar kinds of phenotype classification studies. Thus, the confidence that these clusters
are truly discriminative can be further enhanced.
1.4.3 Disease-specific pathway identification
The most common application of microarray technology in disease research is to identify
genes differentially expressed in disease versus normal tissues. However, in the case of
complex diseases, it is well known that, phenotypes are determined by the underlying
structure of genetic networks, not by individual genes. Thus in many situations, it is the
interaction of many genes that plays an important role in causing phenotypic variations.
In Chapter 4, using cancer as an example, we develop a graph-based method [XKNI+08]
to integrate multiple microarray datasets to discover disease-related co-expression network
modules. We propose an unsupervised method that takes into account both co-expression
8
dynamics and network topological information to simultaneously infer network modules
and phenotype conditions in which they are activated or de-activated.
Using our method, we have discovered network modules specific to cancer or subtypes
of cancers. Many of these modules are consistent with or supported by their functional
annotations or their previously known involvement in cancer. In particular, we identi-
fied a module that is predominately activated in breast cancer and is involved in tumor
suppression. While individual components of this module have been suggested to be as-
sociated with tumor suppression, their coordinated function has never been elucidated.
Here by adopting a network perspective, we have identified their interrelationships and,
particularly, a hub gene PDGFRL that may play an important role in this tumor sup-
pressor network. Consequently, by using a network-based approach, our method provides
new insights into the complex cellular mechanisms that characterize cancer and cancer
subtypes. By incorporating co-expression dynamics information, our approach not only
extracts more functionally homogeneous modules than those based solely on network
topology, but also reveals pathway coordination beyond co-expression.
9
Chapter 2
Automated Multi-dimensional Phenotypic Profiling
2.1 Introduction
The fundamental aim of modern genetics is linking genotype to phenotype. With the
rapid accumulation of genomics data, the lack of phenotype data has become the bot-
tleneck of this process [FS03]. Phenotyping, especially for human subjects, is a labo-
rious process [LL07]. Moreover, researchers often gloss over the complexity of human
phenotypes by reporting only those traits specifically relevant to their studies. For ex-
ample, a given dataset may provide survival information but not the patients’ ages. In-
ferences derived from such data could be biased or even invalidated by undocumented or
poorly documented phenotypic traits. Furthermore, most available phenotype character-
izations are qualitative (categorical) rather than quantitative (continuous). This practice
is problematic for two reasons: the boundaries between categories are often vague or ar-
bitrary [OHB08], and any phenotypic information distinguishing data within a category
is lost.
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In this paper, we address the above issues by developing PhenoProfiler, a computa-
tional framework for predicting the quantitative phenotype information missing from a
genomic dataset. In particular, this method associates each sample of a given dataset
with the relative intensity of a specific phenotype trait. The quantitative measures of
samples across the whole dataset is referred to as a phenotype profile (PP). Examples
include the body weights of individuals, degrees of malignancy in tumor samples, and the
quantitative responses of patients to drug treatments.
The principle of PhenoProfiler is that similar genomic patterns are likely to be asso-
ciated with similar phenotypic patterns [BvD04]. Thus, we can supplement the (incom-
plete) phenotypic information in a given genomics dataset with traits recorded in other
well-characterized datasets. In particular, we focus on the vast accumulated microarray
data. The NCBI Gene Expression Omnibus (GEO) [BTW+07], for example, currently
contains more than 2000 human microarray datasets that systematically document the
transcriptome basis of phenotypes as diverse as heart diseases, mental illness, infectious
diseases, and a variety of cancers.
The intuition behind our method is as follows. Given a training dataset with known
sample description of a phenotype P , for each gene we can derive an association between
its expression profile and this phenotype P . We denote those genes as signature genes, the
expressions of which are strongly associated with the phenotype in the training dataset.
Given a new microarray dataset that is known to be related to the phenotype P , but
the phenotype description of its individual samples are unknown, we aim to estimate the
PP by constructing a sample profile as a real-valued vector that is most similar to the
11
expression profiles of those signature genes in the new dataset. Figure 2.1 illustrates this
approach.
Since the information we borrow from the training dataset is only the association
between the gene expressions and sample phenotypes, we do not directly compare the ex-
pression values between the training and prediction datasets, thus bypassing the data in-
compatibility problem between cross-platform and cross-laboratory microarray datasets.
PhenoProfiler can therefore use as many as possible microarray datasets in the public
repositories in the training stage, and construct a new dataset’s profiles for a wide range
of phenotypes.
We applied our method to 587 human microarray datasets, covering more than four-
teen thousand microarray samples. The predicted phenotype profiles were highly con-
sistent with known phenotype descriptions. We showed that PhenoProfiler can robustly
provide multi-dimensional characterization of the phenotypes missing from a dataset, and
can facilitate the discovery of confounding factors for the transcriptome-phenotype map-
ping. The comprehensive phenotypic data generated by this method will vastly increase
the value of published and forthcoming genomics data.
2.2 Results
2.2.1 Overview of method
As illustrated in Figure 2.1, PhenoProfiler consists of two steps. (1) Given a microarray
dataset D1 whose samples have known descriptions of the phenotype P , for each gene i
12
Figure 2.1 The principles of PhenoProfiler. Each row of an expression matrix corre-
sponds to a gene, and each column corresponds to a sample. The magnitude of gene
expression is indicated by a color scale running from green (low) to red (high). From the
training dataset (left), we obtain for each gene i a coefficient wi describing the degree
of association between its expression level and the phenotype. Here, genes 1 and 2 have
high positive coefficients. Gene 3 shows no clear association with the phenotype, so its
coefficient is close to zero. Gene 4 has a high negative coefficient. Therefore, genes 1,2
and 4 are signature genes of the phenotype. Given a new dataset, for each sample we
aim to estimate the relative intensity of the association between this sample and the
phenotype such that the derived intensity values of all sample are most similar to the ex-
pression values of signature genes. We term such a sample profile as a phenotype profile.
The phenotype profile vector is depicted by the grey cells, where brighter colors indicate
estimated tighter association with the phenotype. After sorting the samples based on the
phenotype profile, it can be seen that the expression profiles of genes 1 and 2 are strongly
correlated with phenotype profile, while that of gene 4 is anti-correlated.
13
we calculate a coefficient wi that indicates the degree of association between its expres-
sion profile and the phenotype P . The appropriate way to calculate wi depends on the
structure of the phenotype descriptions. If the phenotype description is binary, i.e. the
dataset compares two phenotype groups, we can simply use the two-sample t-statistic as
wi. If the phenotype description is continuous, we can use the correlation between the
phenotype values and the gene expression values as wi. Genes with a large magnitude
of wi are termed the signature genes of the phenotype P . (2) In order to predict the
phenotype profile (PP) of a new microarray dataset D2, we use the following constrained
optimization approach. For a dataset with m individual samples, the PP is defined as a
normalized, real-valued vector of m values (p1, p2, . . . , pm)
T (denoted p). We also define
the normalized expression vector of the gene i as (ei1, ei2, . . . , eim)
T , denoted ei; and we
denote the expression matrix containing all such expression vectors as E. Given a set of
coefficients wi determined from the training data, the objective is to find a profile p that
minimizes the weighted least-squares difference min
∑
i |wi|
∑
j(sgn(wi)eij − pj)2. (The
function sgn is +1 or −1 depending on the sign of its argument; we want the phenotype
profile p to be close to ei when wi is positive, and close to −ei when wi is negative.) A
series of matrix computations (see the Methods section) yields the optimal solution pˆ,
which is essentially the normalized weighted (by wi) sum of gene expression values across
samples.
To assess whether the predicted profile pˆ captures the expression trend of those sig-
nature genes, we calculate an association score cˆ, defined as the Pearson’s correlation
14
between the coefficients w and Epˆ (detailed explanation in Methods). To assess the sta-
tistical significance of pˆ, we compare the cˆ to those calculated using the same expression
matrix E and 1000 random permutations of coefficients w.
2.2.2 An illustrative case: reconstructing the temporal order of the
yeast log-to-stationary growth transition
As an illustrative example, consider the two microarray datasets GDS18 and GDS283.
Both study the log-to-stationary growth transition of yeast, but with different microarray
platforms. Both datasets measure gene expression starting at the logarithmic phase and
extending through the stationary phase. Here our goal is to predict changes in yeast
phenotype from log to stationary transition, responding to the depletion of nutrients.
Naturally, the temporal order of the samples serves as a good means of validating the
prediction.
Using one dataset for training, we computed the Spearman’s rank correlation between
individual gene expression profiles and the temporal order of the samples. These statistics
are used as the training coefficients. In the other dataset, we then predicted the phenotype
response profile based on gene expressions, hoping to recover the correct temporal order of
samples. In both cases, the predicted PP was highly consistent with the actual sequence
of samples (Spearman’s rank correlation were 0.83 and 0.79, depending on which dataset
was used for training). Figure 2.2 shows the predicted and the original sample order of
dataset GDS18. Two subgroups are visible in the predicted profile, accurately reflecting
the logarithmic and stationary phases. The sole exception is at the transition between
the two phases.
15
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Figure 2.2 Consistency between predicted and true phenotype profiles in GDS18. Using
GDS283 as the training dataset, the predicted phenotype profile of GDS18 closely matches
the original temporal order of the samples. The original temporal order is measured as
the logarithm (base 10) of minutes.
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Intriguingly, experiment GDS283 stopped taking measurements only 17 hours after
the yeast entered the stationary phase. Experiment GDS18, on the other hand, continued
measurements for another 12 days. It is remarkable that a phenotype signature derived
from GDS283 can accurately sort the phenotype progression of GDS18. This result
demonstrates that the essential physiological changes occurring within and between the
logarithmic and stationary growth phases can be extrapolated as well as interpolated.
2.2.3 Large-scale prediction of phenotype profiles
To test the general applicability of our method, we performed a large-scale analysis of
587 human microarray datasets (see the Methods section for details on data collection
and processing). Datasets containing at least two disjoint sample groups, representing
a phenotype and its baseline (P and P ′), each with at least 10 samples, were selected
as training datasets (D1). If a dataset contains n sample groups, we can generate
(
n
2
)
distinct training datasets. Since the phenotype values in these datasets are categorical,
we use the two-sample t-statistic as coefficients w. By setting the threshold p-value for
the predicted PP to 0.001 and the association score cˆ ≥ 0.25, a total of 37,852 novel PPs
were associated to the 587 datasets.
To validate the method, for each training dataset D1 we also need a testing dataset
D2 that contains the sample descriptions on exactly the same phenotypes P and P
′.
Among all 587 datasets, we only identified 4 training-testing dataset pairs meeting this
criterion, in which each of the testing datasets also contains two sample groups of P
and P ′. To assess whether the predicted phenotype profile is consistent with the known
distribution of phenotypes P and P ′ in the testing dataset, we used the Wilcoxon rank
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sum test. Specifically, in the test dataset, the two sample groups’ (P and P ′) predicted
phenotype values are compared using Wilcoxon rank sum test. A small Wilcoxon p-
value indicates that there is a significant difference between the distributions of predicted
phenotype values for the two groups, therefore the predicted profile is consistent with
known phenotype information. Among the 4 training-testing pairs, all predicted PPs
were highly consistent with the known phenotype groups (Wilcoxon p-value < 10−4).
In order to obtain a general assessment using more validation data, we relaxed the
requirement that the description of the testing dataset exactly matches the training data
phenotypes. In fact, if the phenotypes of a given dataset were even moderately similar
to the training phenotype, the predicted profiles were found to agree well with known
phenotype groups in the testing dataset. This implies a strong interdepedence among
related phenotypes. We quantify the similarity between the training and testing phe-
notype with two measures: (1) the percentage γ of Unified Medical Language System
(UMLS) concepts of the merged sample group descriptions of D1 shared with the dataset
description of D2; and (2) the similarity between the descriptions of corresponding sample
groups in D1 and D2, denoted as s. The latter is defined as the cosine of the angle be-
tween two term frequency-inverse document frequency (tf-idf) vectors of mapped UMLS
terms (See the Methods section for details). Following these measurements, we iden-
tified 32 training-testing dataset pairs with similarity thresholds s > 0.4 and γ > 0.6.
Among these, 81% of predicted phenotype profiles were consistent with prior phenotype
descriptions (Wilcoxion test p-value < 0.05). This result highlights the effectiveness of
our method in exploiting the interdependence of similar phenotypes.
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We further studied the robustness of our method against the size of the training
dataset. We randomly selected a training dataset and a test dataset, and then calculated
the correlation between the PP constructed with the original training dataset and that
with certain amount of training samples randomly removed. Repeating this test 10,000
times with 10% (and 20%) sample removal produced an average correlation of 0.98 (and
0.95) between the resulting PPs and those without any samples removed. Even for those
training datasets with a small size of 10 samples in each of the two phenotype groups,
the obtained PP correlations were still greater than 0.9 for both 10% and 20% sample
removal, demonstrating the robustness of our method.
2.2.4 Multi-dimensional profiling of complex phenotypes
As previously mentioned, a total of 37,852 PPs were derived and assigned to the 587
datasets. On average, each dataset is assigned 65 PPs. In some cases, related train-
ing datasets generated highly correlated PPs, further enhancing our confidence in the
prediction. Two examples are described below.
Dataset GDS2855 studies various forms of muscular dystrophy. Three training sets
(GDS609, 610, and 612) generated highly correlated PPs (average correlation 0.88) for
GDS2855. All three training datasets describe the difference between Duchenne mus-
cular dystrophy and normal muscle tissues, although they were measured with different
platform technologies. Furthermore, all 3 predicted PPs were highly consistent with the
original sample description of GDS2855 (Wilcoxion test p-value < 10−6).
Dataset GDS1962 studies gliomas of different grades, and was assigned four highly
correlated PPs (average correlation 0.9) by datasets GDS1975, 1976, 1815, and 1816.
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All four training datasets focused on comparing grade III and grade IV glioma samples.
Remarkably, the predicted PPs not only did a good job of separating grade III from grade
IV samples in the testing dataset, but also separated grade II from grade III samples. In
addition, the separations followed the order of tumor grades. This example shows that our
method captures the essential difference between high- and low-grade tumors, and thus
can be extrapolated to tumors of grades beyond those represented in the training data.
This ability to extrapolate from the training dataset represents a significant advantage
over traditional classification methods.
A testing dataset is often (78% of cases) assigned multiple uncorrelated PPs (correla-
tion < 0.1) describing different properties of a complex phenotype. For example, dataset
GDS843 contains 49 samples comparing patients with abnormal karyotypes to patients
with normal karyotypes to study adult acute myeloid leukemia (AML). The samples were
collected from peripheral blood or bone marrow. Its predicted phenotypes include three
uncorrelated profiles (see Figure 2.3), which are detailed below.
1. Training dataset GDS842 also studied abnormal versus normal karyotypes in adult
AML patients. The derived phenotype profile is consistent with known sample
description of this phenotype in GDS843 (Wilcoxon p-value 0.04), thus validating
our method.
2. Training dataset GDS2118 compared individuals with refractory anemia to normal
individuals. The PP trained by this comparison is highly correlated (correlation
> 0.9) with two other PPs that also come from training datasets that studied re-
fractory anemia. In fact, the recently proposed WHO classification of hematologic
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Figure 2.3 Multi-dimensional profiling of the dataset GDS843 that compares patients of
adult AML with abnormal karyotypes to those with normal karyotypes. Three different
training datasets produced mutually uncorrelated phenotype profiles (black curves) that
could be assigned to GDS843. The three most significantly correlated expression profiles
of genes known to be related to the respectively profiled phenotypes are superposed in
the three primary colors. For clarity, the samples are ordered according to the first PP,
and the expression profiles of negatively correlated expression profiles have been reversed.
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malignancies merged the disease refractory anemia with excess blasts in transfor-
mation (RAEB-T) into the category AML. However, this new disease classification
is controversial. Although RAEB-T and AML share similar clinical parameters, a
study pointed out that their biological bases are different (e.g. RAEB-T is distin-
guished from AML by a significant increase in apoptosis), and it suggested that
RAEB-T should be regarded as a distinct disease entity [ABO+00]. Therefore,
the derived PP may uncover hidden patient information and possibly help to dif-
ferentiate RAEB-T from AML, which could further lead to improved treatment
design.
3. Training set GDS1221 studies the patient response to the drug Imatinib. Imatinib
was designed to treat chronic myeloid leukemia by reducing the tyrosine kinase
activity of the well-known bcr-abl fusion gene. Our phenotype profile could there-
fore be used to identify patients that would be more likely to respond to Imatinib
treatment.
In summary, while the first PP serves as an internal validation of the method, the
other two PPs provide novel insights into the pathologic and therapeutic properties of
sample phenotypes in the dataset GDS843. The specific phenotype properties represented
by the above PPs can be further confirmed by examining genes whose expressions are
significantly correlated (p-value < 0.001) with these profiles. For example, the AML PP
(number 1 above), has 10 significantly correlated genes that are known to be associated
with the UMLS concept “Leukemia, Myelocytic, Acute.” A particularly interesting gene
is FLT3. A study suggested that in patients with karyotype alterations, a recipricol
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translocation was not sufficient to cause acute promyelocytic leukemia, and that an ad-
ditional mutation in FTL3 may be required [DLCBPS+08]. For the refractory anemia
activation profile, there are 12 significantly correlated genes known to be involved in “Ane-
mia.” These include three Fanconi Anemia genes (FANCA, FANCD2, FANCG) as well
as TGFB1, which may affect the progression of refractory anemia specifically [BBG+05].
Among the genes correlated with the Imatinib response profile, three are tyrosine kinases,
which is consistent with the target of Imatinib [DD03]. This example demonstrates the
power and specificity of our multi-dimensional phenotype profiling approach by utilizing
the large number of microarray datasets.
2.2.5 Discovery of hidden confounding factors in microarray studies
Due to the scarcity of phenotype information in many microarray datasets, confounding
phenotype variables may not be well documented. Thus, caution should be exercised in
deriving inferences from microarray datasets. The following cases provide representative
scenarios.
Dataset GDS1673 examines normal lung tissue from 23 donors, including smoking and
non-smoking individuals. Interestingly, we found that a predicted PP trained on male vs.
female skeletal muscle samples (dataset GDS914) was able to separate the smoking and
non-smoking samples of GDS1673 (Wilcoxon p-value 0.0002). After obtaining additional
phenotype information on the GDS1673 subjects, it turns out that among non-smokers,
which made up almost two-thirds of the sample, females outnumbered males by more than
two to one, while among smokers the numbers of the two genders were approximately
equal. Thus, simply comparing the expression profiles of the smoking versus non-smoking
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groups would not derive the signature of smoking, but rather the mixed signatures of
smoking and gender.
As another example, the goal of the GDS1887 study was to build a prognosis model
for rectal cancer cells responding to radio therapy. According to the GEO annotation, its
46 samples had been separated into training and test groups for model construction and
validation. Surprisingly, we found that the original training and test samples from this
study could be well separated (average Wilcoxon p-value 0.001) by four highly correlated
PPs (average correlation 0.95). All of those four PPs come from training datasets that
compare the cancer to normal tissue or that compare cancers of different malignancies.
This strongly suggest that there were systematic differences in cancer malignancy between
the training and testing samples, even though they were supposed to be generated by
random partition. Any such sampling bias would negatively impact the accuracy of the
prognosis model.
Of course, sampling bias can often be traced to the very limited availability of phe-
notype data in the first place. Our compendium of predicted phenotype profiles
(http://zhoulab.usc.edu/PhenoProfiler) provides a comprehensive description of a large
proportion of the datasets in the GEO database. This knowledge can facilitate an un-
biased understanding of the transcriptome-phenome mapping. It can also serve as the
starting point for the identification of molecular mechanisms shared by different diseases
and phenotypes.
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2.3 Discussion
Phenotypes are complex, and difficult to quantify in a high-throughput fashion. The lack
of comprehensive phenotype data can prevent or distort genotype-phenotype mapping.
This paper describes a novel approach to perform in silicon phenotype profiling. Our
method provides numerous advantages which we outline here. (1) For most datasets we
were able to predict multiple phenotype profiles, which could help researchers to reveal
different aspects of complex diseases and facilitate treatment design. (2) We can provide
a quantitative phenotype description of the sample characteristics. Although “categor-
ical” phenotype description is prevalent, in reality phenotypes constitute a continuous
spectrum. (3) Our method can extrapolate the profiling to classes beyond those repre-
sented in the training data, as illustrated in the glioma case study. This is an advantage
over traditional classification methods. (4) PhenoProfiler avoids direct comparison of
gene expression values from different datasets, and thus can utilize almost all available
microarray data regardless of platform or laboratory. In contrast, traditional regression
methods cannot be directly applied to microarray datasets from different platforms.
The continued accumulation of microarray data will further increase the power of
PhenoProfiler in two aspects: the variety of phenotypes to be profiled, and the confidence
of its predictions. The latter benefit derives from having several mutually correlated
PPs from similar datasets. The principles of our method can be easily applied to other
types of genomics data (e.g. proteomics or metabolomics) as they become increasingly
available. The present work focuses on linear gene-phenotype associations, but more
complex relationships can be devised depending on the data characteristics.
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Our univariate method for selecting the weights from the training sample is only one
of many possible approaches. For example, one could consider constructing weights using
a multivariate procedure that takes into account correlations among the gene expression
levels, such as Fisher’s linear discriminant procedure (i.e Discriminant Function Analysis
for two groups). However, such an approach requires estimating a covariance matrix for
the gene expressions which is not practical given that there are thousands of genes and
a limited number of samples (typically on the order of 10) per dataset. In fact Fan and
Fan [FF08] prove that, when the dimension of the feature space is high, a univariate
two-sample t-test procedure, similar to our approach, is often superior to a multivariate
method. Alternatively, when the important phenotype information can be characterized
using a small number of linear combinations of the genes, dimension reduction techniques
like Nonnegative Matrix Factorization [BTGM04,TSE+07] may also produce meaningful
phenotype predictions.
2.4 Methods
2.4.1 Predicting phenotype profiles by constrained
optimization
From a training microarray dataset, we derive a vector w = (w1, w2, . . . , wn)
T that con-
tains the gene-phenotype association coefficients of n genes. Given a new dataset with n
genes and m samples, and the normalized gene expression matrix E = (eij)n×m, we aim
to obtain the optimal Phenotype Profile (PP) of the m samples, where PP is a normalized,
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real-valued vector p = (p1, p2, . . . , pm)
T that show high similarity to the expression pro-
files of those genes that have high magnitude of gene-phenotype association coefficients
w (termed signature genes)
Q1 : min
p∈Rm
d(E,w,p) =
∑
i
|wi|
∑
j
(sgn(wi)eij − pj)2
subject to
∑
j
pj = 0
1
m− 1
∑
j
p2j = 1
Let b = (b1, b2, . . . , bm)
T be the weighted sum of gene expression values for each
sample, bj =
∑
iwieij . The following theorem provides the solution to the minimization
problem.
Theorem: The solution pˆ to problem Q1 is a vector that is the normalized form of
b. That is,
pˆ =
b− b
σ(b)
where b and σ(b) are the mean and standard deviation of b respectively.
Proof: By expanding the function d, we have
d(E,w,p) =
∑
i
|wi|
∑
j
e2ij +
∑
i
|wi|
∑
j
p2j − 2
∑
i
wi
∑
j
eijpj
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Since p is normalized and E and w are fixed, the first two terms are fixed. So the
minimization problem Q1 can be simplified to an equivalent maximization problem:
Q2 : max
p∈Rm
c(E,w,p) = wTEp
subject to pT1 = 0
pTp = m− 1
where 1 is the vector whose elements are all 1.
Let b = ETw. Let the Lagrangian function for Q2 be
L(p, λ1, λ2) = b
Tp + λ1p
T1 + λ2(p
Tp− (m− 1))
where λ1 and λ2 are Lagrangian multipliers. According to the Karush-Kuhn-Tuker con-
ditions [BSS93] (as the functions bTp, pT1, and pTp are all convex), the solution to
Equation 2.1 contains the global optimum of Q2,
∇L(p, λ1, λ2) = 0 (2.1)
Equation 2.1 results in two solutions: p = ±b−bσ(b) . Since Q2 is a maximization problem,
it is easy to show that the solution of Q2 is pˆ =
b−b
σ(b) , and so is the solution of Q1.
pˆ is regarded as the PP of the new dataset because among all vectors in Rn, pˆ is the
one that most resembles the normalized expression profiles of the signature genes that
were defined by the training data.
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We calculate an association score cˆ as the Pearson correlation between w and Epˆ.
The score is derived from the maximization problem Q2. Epˆ provides the association
between expression profiles and the predicted phenotype profile in the testing dataset.
Thus, higher cˆ indicates higher consistency of gene-phenotype associations derived from
the training and testing datasets.
2.4.2 Data collection and processing
We collected 587 human microarray datasets, each containing at least 5 samples, from
the NCBI Gene Expression Omnibus (GEO) [BTW+07]. For data generated with the
Affymetrix platforms, we increased any values less than 10 to 10 and performed a log
transform of the gene expression values. For genes with multiple probesets present, the
expression values of those probesets were averaged. We then normalized each dataset by
converting the expression values of each gene to Z-scores (zero mean and unit variance).
The 587 datasets yielded 537 training datasets. A training dataset contains two disjoint
sample groups, each of which contains at least 10 samples, representing a phenotype and
its baseline. When performing PP prediction, we discard those training-testing dataset
pairs that share fewer than 100 genes in common.
2.4.3 Automatic processing of phenotype annotations
In GEO, a dataset is usually annotated by a short description paragraph; a sample group
is annotated by a word or a short phrase; and a sample is usually annotated by one
sentence. To systematically categorize the phenotype information associated with each
microarray dataset, we used the Unified Medical Language System (UMLS) [Bod,BK06].
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We mapped the dataset description, sample group descriptions, and sample descriptions
onto UMLS concepts via the MetaMap Transfer program [Aro01]. To reduce noise we
focused on disease-related concepts, including the MeSH vocabulary and the semantic
types “Pathologic Function”, “Injury or Poisoning”, “Anatomical Abnormality”, “Body
Part, Organ, or Organ Component”, “Tissue”, and “Cell”. In general, the higher a
concept is on the UMLS hierarchy, the broader is the concept. Disease concepts at the
fine granularity level may be associated with more clinical significance. In order to infer
higher-order links between datasets, all of the ancestor concepts of mapped concepts were
included.
2.4.4 Measuring phenotype annotation similarity
We measure phenotype similarity between sample groups (the two groups of a training
dataset and the two groups of a testing dataset) by the following procedure. 1) For each
group, we map its title and member sample descriptions onto UMLS concepts. 2) We
then construct a term frequency-inverse document frequency (tf-idf) vector [SB88] for
each sample group. 3) Suppose that U11 and U12 are two tf-idf vectors corresponding
to the two sample groups in the training dataset, and U21 and U22 are tf-idf vectors
corresponding to the two sample groups in the testing dataset. The similarity between the
sample groups is then calculated as max(< U11,U21 > + < U12,U22 >,< U11,U22 >
+ < U12,U21 >), where < a,b > denotes the cosine similarity [LKS
+07] of two vectors
a and b, calculated as a normalized dot product < a,b >= a·b‖a‖‖b‖ . Essentially, this
measure identifies the best match between the sample groups in the training dataset and
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testing dataset while taking into account the possibility that the groups could be matched
in reverse order.
2.4.5 Calculation of TF-IDF vectors of sample groups
Note that a sample group is called “subset” in NCBI GEO. Annotation of a sample group
includes UMLS concepts, mapped from both (1) its text title and (2) all its samples’ text
description. In our experiment, each sample group is viewed as document and each UMLS
concept is viewed as a term. Thus, given 587 human microarray datasets, we collected
4065 documents (sample groups) and 1277 terms (UMLS concepts).
In NCBI GEO annotation of sample groups, its title and each samples’ description
share almost the same set of UMLS concepts. Our practical experiments showed that, in
such complicated annotation environment, the frequency of a UMLS concepts in a sample
group does not indicate the importance of the UMLS concept. So we used only 0 or 1
to represent the term frequency of each UMLS concept. Then IDF of each term (UMLS
concept) is counted based on the binary TF vector of each document (sample group).
Details of how to get TF-IDF is presented in the following formulas:
TFterm, document =

1, if this term occurs in the document;
0, otherwise.
(2.2)
IDFterm = log
(
number of all documents
number of documents this term occurs
)
(2.3)
TFIDFterm, document = TFterm, document × IDFterm (2.4)
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In practical experiments, we noticed that a large portion of UMLS concepts are shared
by two sample groups in the same dataset (e.g., U11 and U12 from the training dataset).
Ideally, we expect that annotation of two sample groups from the same dataset should
reflect their phenotype differences, not commonness. Thus, we mask by zero in TF-IDF
vectors, the common UMLS concepts shared by the same-dataset sample groups, e.g, U11
and U12 (or U21 and U22 from testing dataset), when computing annotation similairty.
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Chapter 3
A Stable Iterative Method for Refining Discriminative
Gene Clusters
3.1 Introduction
Microarray has become an important tool for identifying genes that discriminate sample
phenotype classes because of its power of monitoring the expression levels of thousands of
genes in a single experiment. Finding discriminative genes with gene expression data is
actually the feature selection problem in classification theory. From the machine learning
point of view, it is critical since the gene expression datasets usually contain a small
number of experiments (called samples) and a large number of genes (called features)
in each experiment. The selected highly discriminative genes after filtering out those
non-representative genes which may dilute the pattern in classification computation can
be further studied for the investigation on the biological mechanisms that are responsible
for sample phenotype class distinction.
A number of efforts have been put in searching effective gene selection methods (For
example [GST+99,GWBV02,XFZ01,AM02,FSMJ03,ZLS+06]). Due to the small-sample
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size and high-dimension properties of the sample phenotype classification problem, it is
not difficult to find a feature subset that can perfectly discriminate all the samples [MR03].
In fact, theoretical study in [Cov65] showed that even for the non-informative, randomly
generated dataset, the expected size of a feature subset that can linearly discriminate all
the n samples is just (n+ 1)/2. In microarray data analysis, there can be a large number
of highly discriminative subsets containing only a couple of genes; and each individual
gene in such a subset is not necessarily highly discriminative. For example, we observed
by exhaustive search that there are as many as 10,173 perfect 3-gene subsets for sample
phenotype classification with the weighted voting method proposed by Golub et al and
with their proposed training-test split [GST+99]; and these gene subsets cover 3,337
genes (93.4% of all the 3,571 genes in the datasets after preprocessing). This observation
suggests that a method of finding a highly discriminative compact gene subset is not
enough. The variability of the subsets found by such a method likely hinders the discovery
of real interaction among the genes given that the method is usually sensitive to both the
choice of samples and noise in the microarray data.
The fundamental limit and challenges mentioned above motivates us to design more
robust methods by taking into account the expression similarity information among genes.
In this paper, we identify a series of discriminative gene clusters by running clustering
and feature selection processes iteratively, where the centroids of the clusters are used to
form predictors. This work also shows that the predictor constructed in this way is more
stable and less sensitive to the choice of training samples. Because biological functions are
usually resulted from collective behavior and coordinated expression of a group of genes
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rather than that of an individual gene, genes grouped according to their co-expression
pattern may be more powerful in revealing gene regulation mechanisms.
Our approach to generate discriminative gene clusters is a combination of supervised
and unsupervised technique In recent years, Jornsten and Yu [JY03] and Dettling and
Buhlmann [DB02] proposed similar combination approaches. However, there are major
differences between their methods and our method. We use a multivariate approach for
cluster selection, while Dettling and Buhlmann [DB02] employed a univariate approach,
which assumes the independence of the contribution of clusters to sample phenotype clas-
sification. Although such hypothesis reduces computational complexity for large datasets,
the accuracy is compromised since the complex biological interaction among gene clusters
is not properly reflected. We exploit a multivariate approach in the content of gene expres-
sion analysis since it accounts for the joint contribution of clusters to sample phenotype
classification. It is known that such complex phenotype like cancer is resulted from not
expression of individual genes but rather the underlying genetic networks. Thus a mul-
tivariate approach that emphasize the combinatorial effect of variables is more suitable
to the exploration of the interaction among variables. Our method differs from [JY03]
in the following two aspects: Although both works adopt multivariate approach, first
of all, in their information-based approach, clustering and cluster selection are done si-
multaneously, resulting in a set of clusters optimizing the Minimum Description Length.
In comparison, our computation-oriented approach is a refining process where cluster-
ing and cluster selection are performed alternatively in each iteration step with better
and better results. Secondly, the clusters generated with Jornsten and Yu’s approach
include both active and inactive ones. Here, active clusters are those whose centroids are
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relevant to sample phenotype classification, and inactive ones are not. Our method is
essentially a backward approach [AM02]. It iteratively eliminates the less active clusters
and re-clusters the remaining genes in the active clusters, reducing the negative influence
of non-discriminative clusters on the sample phenotype classification.
Our program outputs a series of cluster sets that have increasing discrimination power
for training samples without losing prediction power on the test samples, as indicated in
our experimental results. It achieved similar or better prediction accuracy than the
known methods aforementioned for most of the tested datasets in our validation process.
More importantly, our test shows that the centroids of the output clusters using different
sets of training samples are stable and consistently achieve significant proximity to the
global optimal gene clusters obtained by using all the samples. Another advantage of our
method is that it provides researchers with flexibility to decide which cluster set should
be chosen for their purpose.
3.2 Results
We implemented the algorithm (described in the Methods section) as MATLAB functions.
It runs on a PC with the Windows operating system. The SVM program written by
Cawley was downloaded from the website http://theoval.sys.uea.ac.uk/ gcc/svm/toolbox.
In this section, we present the detailed test results on both simulated and Leukemia
AML/ALL datasets [GST+99]. We also have tested our method on other real datasets
and compared the performance of our algorithm with those reported in the previous
literature. The details of the performance measures are described in the Method section.
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3.2.1 Simulated datasets
We generated 100 simulated binary classification datasets using a simple stochastic model.
Each simulated dataset contains 100 samples evenly split into two sample phenotype
classes. Both training and test samples contain 25 samples in each class.
Each dataset contains of 400 genes evenly divided into four gene clusters. Two of the
four clusters are relevant to sample phenotype classification and these two discriminative
clusters C1 and C2 contribute to sample phenotype classification independently. Their
centroids χ(C1) and χ(C2) are generated according to the sample phenotype class labels.
Each component of χ(C1) in a position is generated according to normal distributions
N(1, 0.5) or N(-1, 0.5) depending on whether the corresponding sample is in class 1 or
class -1, while each component of χ(C2) generated according to N(-1, 0.5) if the sample
is in class 1 and N(1, 0.5) otherwise. Similarly, the centroids of the non-discriminative
clusters C3 and C4 are generated according to the normal distribution N(1, 1) and N(-
1,1) regardless of the samples’ class. For each i=1, 2, 3, 4, the expression values of a
gene in the cluster Ci are generated according to the multivariate normal distribution
N(χ(Ci), di/4), where di = minj 6=i d(χ(Ci), χ(cj)).
We run our algorithm with the input gene set contains all the 400 genes for each of
the 100 simulated datasets. The performance results are summarized in Figure 3.1. We
observed that the classification performance of the generated clusters keeps increasing as
the iteration process goes. The average classification accuracy of these tests jumps from
0.756 up to 0.848 (Figure 3.1a); and the classification accuracy θtest on training samples
goes up from 0.720 to 0.984 (Figure 3.1b).
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Figure 3.1 The performance analysis on simulated datasets. The solid lines indicate
the average values; and dotted lines indicate one standard deviation from the averages.
The X-axis represents the number of genes in Si. Note that, when the generating process
goes, the number of genes in Si decreases. (a) The classification accuracy θtest on the
test samples. (b) The classification accuracy θtrain on the training samples. (c) The
percentage ρsim (i) of truly discriminative genes in Si; (d) The p-value ρS(i) based on
δˆ(Ai).
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We also observed that more and more truly discriminative genes are identified in the
active clusters as the algorithm proceeds. Since the genes in the discriminative clusters are
known in each simulated dataset, we computed the ratio ρsim(i) =
|Si∩(C1∪C2)|
|Si| of the truly
discriminative genes over all the genes in for each iteration i. The active clusters output
ρsim(i), just before the algorithm terminates is about 0.778 (Figure 3.1c). Recall that,
at each iteration i, the algorithm generates κ = 50 active gene clusters since the number
of training samples nr = 50 for each simulated dataset. We found that at each iteration
i, the centroids of two active clusters are very close to χ(C1) and χ(C2), the centriods of
the discriminative clusters in the model. This is reflected by the indistinguishably small
p-value ρS(i) calculated based on d¯(Ai,∆
′). Here d¯(Ai,∆′) is the ’average’ Euclidean
distance of centroids between an active cluster in Ai and its closest cluster in ∆
′ =
{C1, C2}.
In the same time, the centroids of active clusters become more and more distinguish-
able from each other, increasingly close to the average pairwise distance of all 400 genes,
and such trend can also be reflected by the increasing p-value ρS(I) from 0.228 up to
0.476 (Figure 3.1d), calculated based on δˆ(Ai), the average Euclidean distance between
the centroids of active clusters in Ai. Meanwhile, the Silhouette width ω¯(Ai) of active
clusters in Ai increases from 0.826 to 0.980.
3.2.2 Leukemia dataset
Leukemia AML/ALL dataset [GST+99] contains the expression values of 6,817 human
genes in 47 acute lymphoblastic leukemia (ALL) and 25 acute myeloid leukemia (AML)
tissue samples. After performing the threshold filtering and logarithmic transformation
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procedure, we obtained a reduced dataset with only 3,571 genes. Here, we validate our
algorithm by using three-fold cross validation. In each run, we randomly selected two third
of the samples as the training samples and the rest as the testing samples. The samples
of different phenotype classes are kept proportional in the training and test samples. The
resulting dataset was further normalized by rescaling the variance of expression values of
each gene to 1 in the training samples, and then applying the same rescaling factor to
the expression values of that gene in the test samples.
We conducted the three-fold cross validation for 100 times. To reduce computational
cost, we restrict our algorithm on small portions of discriminative genes. In each run, the
algorithm starts with the input gene set consisting of the 357 genes (10% of all the 3,571
genes) that are highly correlated with the training samples’ phenotype classification in
terms of the correlation metric proposed in [GST+99].
Figure 3.2 summarizes the values of the different performance indicators. The average
classification accuracy θtrain on the training samples ranges from 0.994 up to 1 (Figure
3.2b); and the average classification accuracy θtest on the test samples increase slightly
from 0.966 to 0.972 (Figure 3.2a). These results show that the centroids of the clusters
generated in different iteration steps discriminate the training samples better and better
without significant decrease of its generalization ability.
For the evaluation of our algorithm, we searched for perfect 3-gene subsets, which can
be used to perfectly classify all 72 samples using the weighted voting classifier trained on
all the samples. This search resulted in 9,722 perfect subsets. We selected 48 (roughly
equal to nr) genes gi (1 ≤ i ≤ 48) with highest occurrence frequency to form the cluster
set ∆′1 = {{gi}|1 ≤ i ≤ 48} for comparison with the clusters generated by our algorithm.
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Figure 3.2 The analysis of the three-fold cross validation performance of the algorithm
on the Leukemia dataset. The dotted lines indicate the performance values in individual
tests. The solid lines indicate the average values; and the dotted lines indicate one
standard deviation from the averages. The X-axis represents the number of genes in Si.
(a) The classification accuracy θtest on the test samples. (b) The classification accuracy
θtrain on the training samples. (c) The p-values ρS(i) based on d¯(Ai,∆
′1). (d) The p-
values ρS(i) based on d¯(Ai,∆
′2). (e) The p-value ρall(i) based on δˆ(Ai). (f) The average
Silhouette width ω¯(Ai) of active clusters in Ai.
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We also evaluate our algorithm using another cluster set ∆′2, the final set of active
clusters generated by our algorithm with S′ as the input gene subset and with all the
72 samples as the training samples, where S′ is the set of the 357 genes (10% of all the
3,571 genes) that are highly correlated with the AML/ALL sample classes in terms of the
correlation metric proposed in [GST+99].
Probably because of the selection sensitivity of the correlation metric of [GST+99]
resulting from small sample size, the gene sets that are selected according to different
training-test splits do not have many genes in common. In all the 100 validation exper-
iments, only 120 genes appearing in every input gene set . This number is quite small
compared with 1,071, the number of the genes appearing in some input gene sets (each of
size 357). By contrast, the centroids of clusters in the set generated in each of iterations of
our algorithm in different runs are significantly similar to the selected discriminative genes
in ∆′1 and ∆′2 at most iteration steps. This is reflected by the very small p-values ρs(i)
computed based on d¯(Ai,∆
′
1) and d¯(Ai,∆
′
2), which range from 4.11×10−2 to 6.12×10−3
(Figure 3.2c) and from 5.62× 10−3 to 2.38× 10−3 (Figure 3.2d) respectively. The above
observation strongly suggests the stability associated with discriminative clusters rather
than with individual discriminative genes. Such stability is one of the main advantages
of our method.
We further studied the biological function of genes in the active clusters using Gene
Ontology (GO), focusing on the biological processes located at the fifth level of the GO
hierarchy. For the set of all genes from active clusters in Ai, we find its enriched biolog-
ical processes by calculating the hyper-geometric p-value, then convert the p-value into
a log score s by s = − log10(p). Table 3.1 gives the top four biological processes that
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Biological process Average score
Inflammatory response 2.72
Regulation of catalytic activity 2.19
Response to wounding 1.98
Positive regulation of metabolic process 1.95
Table 3.1 Significantly enriched biological processes
are most significantly enriched in the active clusters in the final iteration, in terms of
the score averaged from the 100 validation experiments. All four processes are frequently
associated with leukemia. In addition, we inspected the change of proportion of the genes
of the four processes in the active clusters during refinement iterations. The proportions
are also averaged over the 100 validation experiments. Figure 3.3 shows that when the
active clusters contain less than two third genes in input gene set S, the average gene
proportions of all four processes monotonically increase until the last iteration. Such
convergence strongly suggests that our method can indeed refine clusters into biologi-
cally meaningful ones. Interestingly, processes of inflammatory response and response
to wounding showed very similar convergence patterns. In fact, these two processes are
closely related. The same holds for biological processes of regulation of catalytic activity
and positive regulation of metabolic process.
3.2.3 The performance analysis on other real datasets
Besides the above dataset, we also tested our algorithm on seven other datasets. The
descriptions of these datasets are as follows. Altogether, we derive 12 sample phenotype
classification studies from the 8 datasets.
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Figure 3.3 Average proportion of genes of the four biological processes during the refine-
ment iterations. The solid black, blue, red, and green lines corresponding to the ordered
processes in Table 3.1 from top to bottom.
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1. ALL T/B Cell dataset. The 47 ALL samples in Leukemia ALL/AML dataset
in [GST+99] are further divided into 39 T-cell samples and 9 B-cell samples.
2. Breast cancer dataset [WBD+01]. This dataset comprises 7,129 genes and 49 sam-
ples being divided into two sample phenotype classes according to their estrogen
receptor (ER) responses: 25 for ER positive and 24 for ER negative.
3. Carcinoma dataset [NASL01]. It contains the expression levels of about 6600 genes
in 18 tumor and 18 normal tissues.
4. Colon dataset [ABN+99]. It consists of the expression levels of 6,500 human genes
in 40 tumor and 22 normal tissues.
5. Diffuse Large B-Cell Lymphoma (DLBCL) dataset [SRT+02]. It consists of expres-
sion values of 6,817 genes in 58 DLBCL and 19 Follicular Lymphoma.
6. The Melanoma dataset [BMC+00]. The dataset consists of the expression ratios
of 6,971 human genes in 12 Unclustered Cutaneous Melanomas and 19 Cutaneous
Melanomas samples.
7. Prostate dataset [SFR+02]. The dataset consists of the expression levels of 52
prostate and 50 normal samples of 6,744 human genes.
8. The Small, round blue cell tumors (SRBCT) dataset [KWR+01]. It consists of 88
samples divided into five sample phenotype classes: neuroblastoma (NB) (18 sam-
ples), rhabdomyosarcoma (RMS) (25 samples), Burkitt lymphomas (BL) (11 sam-
ples), the Ewing family of tumors (EWS) (29 samples) and others (5 samples). The
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dataset has 2,308 genes. Since we consider the binary sample phenotype classifica-
tion problem, we derived four binary sample phenotype classification datasets from
this dataset using the one-against-all rule: SRBCT-NB, SRBCT-RMS, SRBCT-BL
SRBCT-EWS. RFERENCES
We preprocessed each dataset by applying filtering and logarithm transformation if
necessary. For each sample phenotype classification study, we run our algorithm 100
times by choosing random training-test splits in the same way as the Leukemia dataset
described in the last subsection. The performance of our method is summarized in Table
3.2. In the table, there are two columns for each performance measure, indicating the
average values of the corresponding measures at the first and last iteration step of our
algorithm. Because the exhaustive search of the most frequent globally optimal genes
for constructing ∆′1 is time-consuming, we only compare the active clusters with ∆′2
constructed as follows: 1) we apply our algorithm on all samples in the dataset and 2)
use the active clusters of the last iteration as ∆′2.
The classification accuracy θtest on the test samples shows that among 9 of 12 sample
phenotype classification studies, the prediction performance of active clusters in Aj in-
creases slightly from the start to the end of each execution, which are highlighted in the
table. The value of θtest for the remaining three studies (Breast, Colon and Carcinoma)
decrease slightly. The above observations indicate that for all datasets we tested, there is
no significant decrease in the generalization ability of the active clusters Ai in obtained
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Datasets θtest ρS(i) based on d¯(Ai,∆
′
2) ρall(i) based on δ¯(Ai) ω¯(Ai)
Leukemia
ALL T/B
cell
0.97 0.977 1.72E-02 8.28E-03 0.088 0.331 0.406 0.973
Breast 0.843 0.842 1.33E-02 8.36E-03 0.142 0.421 0.351 0.974
Carcinoma 0.983 0.981 2.96E-02 3.20E-02 0.194 0.252 0.382 0.966
Colon 0.814 0.806 2.43E-02 2.06E-02 0.75 0.755 0.673 0.978
DLBCL 0.896 0.929 8.75E-02 1.99E-02 0.441 0.514 0.716 0.982
Melanoma 0.913 0.921 1.71E-02 2.25E-02 0.129 0.463 0.272 0.957
Prostate 0.889 0.916 4.79E-02 2.27E-02 0.495 0.541 0.68 0.987
SRBCT-
BL
1 1 3.63E-04 7.52E-05 0.314 0.322 0.682 0.984
SRBCT-
EWS
0.956 0.986 5.06E-04 9.17E-05 0.297 0.408 0.634 0.984
SRBCT-
NB
0.989 0.996 2.99E-04 6.42E-05 0.321 0.436 0.665 0.986
SRBCT-
RMS
0.974 0.98 4.82E-04 8.18E-05 0.304 0.347 0.63 0.989
Lukemia
AML /
ALL
0.966 0.972 5.62E-03 2.38E-03 0.212 0.398 0.627 0.98
Table 3.2 The performance of the algorithm for different sample phenotype classification
studies.
in each iteration step. The classification performance θtrain on the training samples in-
creases in all of the 12 studies, which indicates that the separation of the training samples
improves for all studies.
All the 100 input gene sets S vary a lot in different runs for each study. There are
only 1.1% to 5.1% of all the genes appearing in all the 100 input gene sets S, while at
least 23.8% to 51.7% genes appear in some input gene sets. By contrast, the centroids
of clusters in SAi generated by our algorithm at each iteration step i are stably close
to the optimal centroids of clusters in ∆′2 as reflected by the p-values ρs(i) ranging from
2.99×10−4 to 8.75×10−2 at the first iteration step and those ranging from 6.42×10−5 to
3.20 × 10−2 in the last iteration step. The consistent closeness of the clusters generated
in different repeats can also be reflected in the standard deviation of ρs(i), which are
limited from 0.32 to 0.96 times of the absolute values of in the first iteration step and
0.24 to 1.37 times at the last iteration step.
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During the generation process, the p-values ρall(i) of average pairwise distance δˆ(Ai)
among centroids of clusters in Ai keeps increasing for all 12 studies (ranging from 0.088 to
0.750 at the first iteration step and from 0.252 to 0.755 in the last step), and the average
Silhouette width of active clusters ω¯(Ai) keeps increasing for all the 12 studies (ranging
from 0.230 to 0.698 at the first iteration step and from 0.964 to 0.989 in the last iteration
step). This indicates that the clusters in Ai are more and more distinct in general.
In summary, our test shows that on real microarray datasets, our algorithm is able
to generate clusters that separate the training samples with increasing prediction accu-
racy and closeness to known optimal clusters. Such discriminative cluster refinement is
consistent with what we have observed on simulated datasets.
3.2.4 Comparing the sample phenotype classification
performance to other studies
In this section, we compare the cross validation performance of our method with pre-
vious works reported in [JY03, DB02, SRT+02, JSR02]. For the purpose of comparison,
we converted the classification performance from the classification accuracy θtest into the
error rate. Table 3.3 summarizes the comparison of our algorithm (of both binary and
multi-sample phenotype class versions) with others by the cross validation error rates. It
is difficult to make direct comparisons with other approaches in the literature, because
the specific data sets or data preparation are not always available. However, the perfor-
mances our method is in general comparable to others. In the comparison, the DLBCL
and Carcinoma datasets are validated using leave-one-out validation; and the remaining
datasets are validated using three-fold cross validation.
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Datasets Our algorithm Dettling and
Buhlmann
(2002)
Jornsten and
Yu (2003)
Shipp et al.
(2002)
Lukemia AML/ALL 3.43 - 2.57 6.58 - 2.71
Leukemia three
classes
13.8 - 9.3 12.6
Breast 16.14 - 14.11 3.00 - 0.75
Carcinoma 5.6 - 0.0
Colon 19.41 - 18.23 23.35 - 15.95 13.6
DLBCL 8.7 - 7.4 7.8
Prostate 11.09 - 8.36 16.47 - 6.91
SRBCT multi class 5.92 - 4.27 5.76 - 0.43
Table 3.3 Comparison of our algorithm with others.
Dettling and Buhlmann [DB02] reported the error rate of their algorithm for different
datasets. They employed nearest neighbors and aggregated trees as the classifiers in their
three-fold cross validation test. For the leukemia AML / ALL dataset, our algorithm
seems to achieve a slightly lower error rate than theirs. In the Colon and Prostate datasets,
the error rate of our algorithm lies between that of theirs. For the Breast dataset, the
error rate is significantly higher than that of Dettling and Buhlmann’s. However, we
obtained the performance using all the original 49 samples. The error rate in each test
ranges from 7.89 to 6.90. According to [WBD+01], at least 7 out of the 49 samples are
inherently erroneous. In comparison, Dettling and Buhlmann [DB02] used the 38 good
samples selected by [WBD+01], and the error rate ranges from 1.14 to 0.10. The 38
samples used in Dettling and Buhlmann [DB02] consists none of the above 7 erroneous
samples. Thus, we believe that the performances of ours and Dettling and Buhlmann’s
are still comparable for the Breast dataset.
For the DLBCL dataset, the leave-one-out performance of Shipp et al. [SRT+02] is
in our performance range. For Carcinoma dataset, Jaeger et a. [JSR02] achieved perfect
leave-one-out performance, and our best performance can match theirs. For the Colon
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dataset, both ours and Dettling and Buhlmann’s error rate are higher than Jornsten and
Yu’s.
We also test the performance of the multiple-sample phenotype class version of our
method against other methods. For the Leukemia three-class dataset, our method is
comparable to Jornsten and Yu’s method. However, for the SRBCT multi class dataset,
our algorithm seems had a slightly higher error rate than that of Dettling and Buhlmann’s.
3.3 Conclusions
Due to the small-sample-high-dimension nature of the microarray dataset, it is not diffi-
cult to find highly discriminative gene subsets of small size. However, if a gene selection
process is unstable with the choice of training samples, the biological significance of the
resulting gene subsets is often not guaranteed. In this paper, instead of finding individual
discriminative genes or gene subsets, we propose a novel backward approach for gener-
ating a series of highly discriminative gene clusters. Compared to selection of individual
discriminative genes, genes grouped in these clusters are more stable when subject to
change of training samples. Therefore they could provide more convincing support to
gene interactions that are associated with the sample phenotype classes. In future, we
will work with biologists to study the biomedical implication of these clusters.
Regarding to the sample phenotype classification performance, the gene clusters pro-
duced by our approach can generally achieve good cross validation performance compared
to the existing methods for most of datasets we tested. More importantly, our test exper-
iments show that regardless of the choice of training samples, the centroids of the clusters
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generated are stable and significantly close to the known optimal gene clusters found using
all the samples. All these indicate that our approach is promising. However, the current
version of our algorithm is time-consuming. In future, the computational efficiency will
be investigated. On the other hand, we used K-means algorithm, a typical partitioning
based clustering method to seek a certain number of clusters that minimize the sum of
squared distances between each gene and its centroid. The drawback for K-means is the
subjective specification of input parameters such as the number of clusters and initial
centroid locations. For unknown microarray datasets, such information is unavailable.
Furthermore, different input parameters may result in significantly different clustering
results. K-means can only converge to local optima, rather than the global optimum. In
order to address these problems associated with K-means clustering. We plan to apply
a novel clustering method based on Random Matrix Theory (RMT) [ZW08] which is
completely objective and do not require the specification of cluster number and initial
centroid locations. RMT method avoids being trapped into local optima. Furthermore,
most previous clustering methods including K-means and hierarchical clustering parti-
tion members into non-overlapping groups. The RMT method allows the same genes in
multiple groups to reflect the fact that a single gene may contribute to multiple biological
pathways.
In order to test the discriminative power of a certain gene cluster, additional criteria
established by statistical analysis should also be conducted to identify and remove inactive
cluster. For example, gene expression pattern observed in the active clusters should
be less likely to appear in the control set. Chi Square test might be used to test the
significance. Some data normalization technique may be considered in the preprocessing
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step to improve the data quality. Furthermore, more suitable backward feature selection
method needs to be exploited so that the gene clustering and cluster selection processes
can be integrated better. Our approach provides a flexible framework that allows us to
test the performance of various computing modules in a various ways of combinations.
Our method can not only be easily extended to multi-sample phenotype class predic-
tion, but also can be easily extended to integrate gene clusters obtained from multiple
datasets that contain sample phenotype classification study of same type. Such integra-
tion can be obtained by counting the occurrence frequency of a gene in similar clusters
obtained from different datasets. In such way, by pulling evidences from multiple datasets
from different experimental sources, genes in such clusters of high occurrence frequency
would have higher confidence to form truly discriminative gene sets.
3.4 Methods
3.4.1 Algorithm
In this subsection, we present our backward approach for generating discriminative gene
clusters. The method is executed in a repetitive manner. In each pass, the method first
groups genes into clusters that may indicate functional categories [THC+99]. It then
ranks the generated clusters and eliminates those clusters that are less discriminative so
that the re-clustering of remaining genes can generate modules with better resolution and
stronger association with the sample phenotype classes. In the clustering stage, we use
the K-means method to group the genes into a constant number of active clusters.
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In the elimination stage, we use a backward feature selection method. This stage
involves cluster validation and evaluation of the discriminative ability of active clusters.
To validate clusters, we use the Silhouette width [KR90] to measure their validity. Assume
the input genes are partitioned into p clusters Ci, C2, . . . , Cp. Given a gene g, let w¯g be
the average Euclidian distance between g and another gene within the same cluster, and
let b¯gJ the average Euclidian distance between and a gene g in a different cluster CJ .
Then the Silhouette width ωg of g is defined as ωg =
minJ (b¯gJ )−w¯g
max(minJ (b¯gJ ),w¯g)
, and the Silhouette
width of a cluster is defined as the average Silhouette width of all its members. It is easy
to see that the Silhouette width of a cluster fall within the range from -1 to 1. A good
cluster should have a high Silhouette width.
To measure the discriminative ability of an active cluster, we adopt the idea of SVM-
RFE method in [GWBV02]. Support Vector Machine (SVM) is a binary-class prediction
method originated from statistical learning theory [Vap00]. A linear SVM first finds a
decision hyperplane y = wTx + b that maximizes the separation between samples of two
classes; and then it does class prediction according to the relative location of a new sample
with respect to the hyperplane in the feature space. Note that the weight vector w found
by the linear SVM indicates the relative importance of the genes for the classification.
Here, we iteratively train a linear SVM and eliminate a gene cluster based on an overall
evaluation on both the weight and the Silhouette width instead of discarding single gene in
the original SVM-RFE method. Such systematic approach makes the elimination process
to better reflect the underlying biological meaning.
Our method is summarized into the algorithm in Figure 3.4. In the algorithm, ∆
denotes the set of inactive gene clusters; Ai denotes the set of active clusters at each
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iteration i; Si denotes the set of genes under consideration at the beginning of the iteration
i; κ denotes the number of clusters partitioned at each iteration step. For simplicity, we
set κ to be nr, the number of training samples.
Figure 3.4 The algorithm of selecting discriminative clusters.
It is often difficult to determine how many clusters the genes should be grouped into
for microarray datasets, which usually have complex expression patterns. The algorithm
outputs κ = nr, the number of the training samples, active clusters in each iteration.
This is because the expected size of a feature subset that can linearly discriminate all
the samples is only (nr + 1)/2 [MR03]. Note that if the feature number is too small, the
clustering will lose its resolution.
Recall that the K-means clustering method starts with an initial partition of the genes.
In order to make it more deterministic in Step 2, we first select κ genes as follows: Find
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a furthest gene pair and form an initial gene set G, and then iteratively find a gene with
largest average Euclidean distance from the genes in G and add it into G until |G| = κ.
We then partition all the genes into clusters by merging each gene with its nearest gene
in G.
The calculation of the Silhouette width of each cluster in Ai takes all the clusters in
both sets Ai and into account ∆. At the ith iteration, the algorithm groups all the genes
in the set Si into κ clusters, forming the cluster set Ai, and then insert the least active
cluster into the inactive cluster set ∆ in Step 5 as follows.
There are two important factors to evaluate in order to determine which cluster should
be removed from Si and added into ∆. The first factor is the cluster’s Silhouette width.
Another factor is the cluster’s discriminative ability in terms of its weight determined by
the linear SVM constructed in Step 4. Here, we would like to eliminate a least discrim-
inative cluster whose centroid is sufficiently representative of the expression pattern of
the cluster (measured by the Silhouette width). In other words, we eliminate a set of well
clustered genes whose expression patterns have little contribution to classification. On
the other hand, those not well clustered genes will be re-clustered at later iterations.
Since the above two factors are not always consistent, we adopt a multiple objective
optimization technique appearing in [Gen] to find a nice tradeoff between these two factor
and such multiple objective method is shown in Figure 3.5.
Finally, we can extend the algorithm to the multiple-class case by adopting the popular
one-against-all approach. In this approach, given a training test split, both training and
test samples of a dataset of K > 2 classes are transferred into K binary classification
problems, each corresponding to classify samples from one class against samples from all
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Figure 3.5 Multiple objective optimization procedure for cluster elimination.
remaining classes. Then our algorithm executed on the K problems results in K series
of active cluster sets Aj,i, j = 1, . . . ,K. Then classifiers are constructed using K × κ
clusters from the K active cluster sets A1,i1 , . . . , AK,iK by selecting i1, . . . , iK such that
|Si1 |, . . . , |SiK | are roughly identical. Given the centroids of the above K × κ clusters, a
multi-class linear SVM is trained using training samples and tested on test samples.
3.4.2 Performance measures
We validate our method in terms of its classification performance and clustering perfor-
mance. The classification performance is determined by the classification accuracy on
training or testing samples. We use the SVM as the classifier to evaluate the generated
gene clusters. Classification accuracy θtest on the test samples is defined as the percentage
of the correctly classified samples. However, we define classification accuracy θtrain on
training samples as the average accuracy of the 10-fold cross validation on the training
samples as suggested in [AM02] for less biased estimation of classification performance.
The clustering quality is measured in terms of the density of the clusters, as well as
the distinction between clusters and the closeness of the clusters to some reference clus-
ters. They are measured respectively by (a) the average Silhouette width ω¯(Ai) of active
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clusters in Ai produced in iteration i, (b) the average Euclidean distance δ¯(Ai) between
the centroids of active clusters in Ai and (c) the ’average’ Euclidean distance d¯(Ai,∆
′)
of centroids between an active cluster in Ai and its closest cluster in a reference cluster
set ∆′ (the construction can be found in the Result Section). To be more precise, assume
Ai = {C1, . . . , Cκ} and ∆′ = {D1, . . . , Dκ}. First, from 1 to κ, find recursively C ′l ∈ Ai
and D′l ∈ ∆′ such that d(x(C ′l), x(D′l)) = minC′l∈Ai−A′′,D′′l ∈∆′−∆′′l d(x(C ′′l ), x(D′′l )), where
x() denotes the centeroid of a cluster, d(, ) the Euclidean distance between two vectors,
A′′ = {C ′1, . . . , C ′l−1} and ∆′′l = {D′1, . . . , D′l−1}. Then, the ’average’ Euclidean distance
d¯(Ai,∆
′) is defined as d¯(Ai,∆′) = 1κ
∑
i≤l≤κ d(x(C
′
l), x(D
′
l)).
We measure the statistical significance of average distances in both case (b) and
(c) at each iteration i against the pairwise distances of all genes in the input gene set
S in terms of the p-value ρS(i), and against all the genes in the dataset in terms of
the p-value ρall(i). In each case, the p-values are calculated according to the empirical
distribution (null distribution) of the pairwise distance of genes randomly sampled in the
whole dataset.
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Chapter 4
An integrative approach to characterize disease-specific
pathways and their coordination
4.1 Introduction
The recent development of microarray technology has significantly facilitated the iden-
tification of disease-related genes [SC03, CCS+02, GST+99, LMA06]. However, many
complex disease phenotypes are caused not by individual genes, but by the coordinated
effect of many genes. Insight into the structure and coordination of disease-related path-
ways is crucial to understanding the pathophysiology of complex diseases. However, it has
proved difficult to infer pathways from microarray data by deriving modules of multiple
related genes, rather than individual genes. The major challenges are: (1) Genes in-
volved in a pathway may exhibit complex expression relationships beyond co-expression,
which may be overlooked by standard microarray analysis methods such as clustering
[ZKH+05]. (2) Pathways are dynamic and the current static annotation of pathways may
not serve as a good template. In fact, pathways are manual dissections of the underlying
dynamic gene regulatory network. Under different conditions, different segments of the
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ensemble network will be activated, leading to condition-specific activation of pathways
[YMH+07].
In this study, by integrating many microarray datasets we propose a novel method to
simultaneously infer pathways and disease/phenotypic conditions under which the path-
ways are activated. The identified pathways may comprise genes with complex expression
relationships beyond co-expression. Due to the existence of a large amount of cancer
microarray data, we used cancer as our case study. We collected a series of microarray
datasets measuring different types of cancers, and a series of datasets measuring other cel-
lular/physiological conditions. We first construct a differential co-expression network, in
which each node represents a gene and each edge indicates a gene pair that is frequently
co-expressed in cancer datasets but not in non-cancer datasets. We then dissect the
networks into cancer-subtype specific network modules by considering (1) co-expression
dynamics and (2) network topology. Figure 4.1a illustrates the conceptual pipeline of
our method.
To measure co-expression dynamics, we use second-order expression similarity, which
we proposed previously [ZKH+05]. Briefly, if we define first-order expression similarity
as the expression similarity of two genes from one dataset, then second-order similarity
measures whether two gene pairs simultaneously exhibit either high or low expression
similarity across multiple datasets. In general, high first-order similarity suggests the ex-
istence of a functional link between two genes, and clustering based on the second-order
similarity captures multiple functional links always activated and deactivated under sim-
ilar conditions. Such functional links are likely to comprise a functional module. Inter-
estingly, genes in a second-order cluster may not always have high first-order similarity
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Figure 4.1 Overview of analysis procedure. (A) Flow chart of the analysis pipeline. (B)
Schematic illustration of the concept of second-order similarity. It is obvious that the
overall expression similarity between the two gene pairs (genes 1 and 2 versus genes 3
and 4) is not significantly high, but their first-order expression correlation profiles exhibit
high second-order similarity. (C) Schematic illustration of the dissection of differential
co-expression networks into network modules based on the co-expression dynamics and
network connectivity. In the heat map, every column corresponds to a dataset and every
row corresponds to a gene pair. Red, black, green and grey corresponds to positive,
low, negative and missing correlations, respectively. By hierarchical clustering, the gene
pairs fall into two major second-order clusters. The 9 gene pairs in the green cluster
comprise three connected network components, whereas the 6 gene pairs in the red cluster
give rise to three connected components. Furthermore, by considering the second order
cluster of a higher level of the hierarchy, which consists of both green and red clusters,
the six networks are united to form two connected networks, reflecting the hierarchical
modularity of cancer co-expression networks.
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(see an example in Figure 4.1b); therefore, second-order analysis allows us to identify
functional modules that are inaccessible to co-expression analysis.
Given multiple gene pairs sharing high second-order similarity, we further divide them
into network components based on their connectivity on the differential co-expression
graph (see an example in Figure 4.1c). We observe that genes within a connected
network component are more likely to participate in the same specific pathway than those
between different components, which, in turn, are likely to be involved in different relevant
pathways. This may reveal high-order cross-pathway coordination. In fact, hierarchical
clustering of differentially co-expressed gene pairs based on their second-order similarity
results in a hierarchical modularity in terms of relevance of functional links. We designed
a linear scaling model to select modules by considering both module size (number of
edges) and within-module second-order similarity. Then, given selected modules, we can
further infer datasets (phenotypic conditions) in which a module is activated, i.e. in which
genes in the module coordinate.
Applying our methods to 32 cancer-related microarray datasets, and 23 non-cancer
related datasets, we derived 162 second-order clusters consisting of 224 network modules,
activated either in cancer or in specific cancer subtypes. In particular, we identified a
breast cancer specific network module that involved in tumor suppression via platelet-
derived growth factor (PDGF)-like signaling, more importantly, a hub gene PDGFRL
that may play an important role in this tumor suppressor module.
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4.2 Results
4.2.1 Network properties of the cancer differential
co-expression network
We curated 32 human microarray datasets (1,764 expression profiles in total) measuring
cancers of 12 tissues, and 23 datasets (1,158 expression profiles) not related to cancer
(e.g. normal tissues, chronic granulomatous disease, Huntington’s disease, inflammatory
response). We first identify gene pairs which consistently demonstrate higher correlation
in cancer versus non-cancer datasets based on a robust correlation estimator, the normal-
ized Percentage Bend correlation (for details see Methods). In following sections, if not
specified, the term correlation will by default refer to the normalized Percentage Bend
correlation. These criteria result in 6,035 gene pairs covering 1,967 genes. The 6,035 gene
pairs, each representing a potential conditional functional link, can be represented as a
differential co-expression network. In this network, each gene is represented as a node
and each differential co-expression relationship is represented as an edge.
It has been reported that co-expression networks follow a scale-free node degree distri-
bution [JMRWK04]. We observed that the differential co-expression network also follows
such a topology, where only a small number of nodes act as “highly connected hubs” (see
node degree distribution in Figure 4.2). This indicates that most gene-gene co-expression
relationships differing between cancer and other phenotypes are associated with only a
few “hub” genes. Such hub genes exhibit a high degree of coordination with many other
genes in neoplastic states, and are therefore likely to play important roles in carcino-
genesis and cancer progression. In fact, most hub genes fall into two main functional
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categories: 1) core processes of neoplastic states such as cell division and chromosome or-
ganization; or 2) dynamic interactions between cancer cells and their microenvironment
such as angiogenesis, immune response, and cell adhesion . For those hub genes with
unknown functions, we can predict their cancer-related functions based on their neighbor
genes. For example, the 16 out of the 33 interacting partners of the ADP-ribosylation
factor-like 6 interacting protein (ARL6IP) are involved in cell division (hypergeometric
test p-value 1.6× 10−24). Thus, ARL6IP is likely to be involved in cell proliferation, con-
sistent with its initial characterization as an interaction partner of the Ras superfamily
member ARL6 [PBG+00]. As another example, while microfibrillar-associated protein 2
(MFAP2) has long been known to bind to various components of the elastic extracellular
matrix [JSOP01], it has not been clear whether it serves more than a mechanical func-
tion. We found that 6 out of its 24 neighbor genes are involved in cell adhesion (p-value
7.7× 10−5). In fact, a recent study found that MFAP2 binds to a neighbor gene Notch1
and activates it [MLH+06].
In the differential networks, we selected the top 112 hub genes that have degrees
≥ 22, such that they together account for 30% of the total degrees on the differential
co-expression networks. Many of those genes fall into two main functional categories:
1) core processes of neoplastic states such as cell division and chromosome organization
(36 genes); or 2) dynamic interactions between cancer cells and their microenvironment
such as angiogenesis, immune response, and cell adhesion (24 genes). Genes falling into
category (1) include TUBB (participates in microtubule-based movement; node degree
70), CKS1B (cell cycle; node degree 43), KPNA2 (regulation of DNA recombination;
node degree 44), RRM1 (DNA replication; node degree 41), MAD2L1 (cell cycle; node
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Figure 4.2 Node degree distribution on the differential co-expression networks.
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degree 49), and SOX2 (establishment/maintenance of chromatin architecture; node degree
30). Genes in category (2) include MAP2K7 (response to proinflammatory cytokines;
node degree 50), TYROBP (cellular defense response; node degree 37), CD4 (immune
responses; node degree 45). They are all reported to play a role in cancer pathogenesis
and progression. In addition, hub genes in the category (1) behave as hub genes across
most of datasets, while those in the category (2) tend to be in hub genes only in solid
tumor datasets.
4.2.2 Identification of pathway modules specific to cancer or cancer
subtypes
The differential co-expression network provides a summary of co-expression links fre-
quently active across all types of cancers. However, it does not provide clues as to
which set of links tend to be simultaneously active and inactive under which types of
cancer. That is, the edges of a differential co-expression network may not be active in
the same subset of datasets. In fact, the largest connected component of the differential
co-expression network contains 5944 edges, which comprises 98% of all the edges in the
network. Thus, based on connectivity alone we cannot break the network into functionally
coherent and cancer-subtype specific modules.
To dissect the networks, we integrate two types of information, the co-expression
dynamics and the network connectivity, to extract cancer-subtype specific network mod-
ules. First, we employ the second-order clustering approach to utilize the co-expression
dynamics information. This includes two steps: (i) for any two genes connected with
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an edge in the differential co-expression network, we calculate the expression correla-
tion in each of the 32 cancer microarray datasets and store it in a vector, termed the
first-order expression correlation profile of the genes; (ii) we then perform hierarchical
clustering of all the gene pairs based on the Euclidean distance between the first-order
expression correlation profiles. Unlike commonly used clustering approaches, the unit of
the second-order clustering is a gene pair instead of a gene, and the distance between
units is computed based on the first-order expression correlation profiles instead of the
original gene expression profiles, hence the term “second-order” clustering [ZKH+05].
Since each edge represents a frequently occurring co-expression relationship in multiple
cancer datasets, it likely represents a functional link. If a cluster of gene pairs follows
the same co-expression pattern across multiple cancer datasets, it represents a module of
functional links being turned on or off simultaneously across different cancer phenotypes.
Given a second-order cluster of gene pairs, we further identify connected network com-
ponents among them. We suggest that a set of gene pairs is more likely to be functionally
related if they form a connected component. We found that the disjoint network mod-
ules of same second-order cluster generally fall into different functional categories. From
the 162 second-order clusters, we measure the functional similarity of genes within each
connect network, and between networks of the same cluster using number of shared Gene
Ontology functions. A t-test of the distinction in functional similarities gives p-value
1.6× 10−8 on our selected network modules shows that the genes tend to be significantly
more functionally coherent within a network than between networks. Thus each network
is more likely to represent a pathway. But in addition, these networks are in the same
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second-order cluster, this indicates that these networks are activated together in certain
phenotypes.
Given a second-order hierarchical clustering tree, we traverse the tree bottom up to
retrieve connected network components. In general, the size of a connected component
(S, the number of edges) decreases with the second-order diameter (D), defined as the
largest pairwise second-order distance. We found that S and D show a linear scaling
relationship in a logarithm scale (Figure 4.3). We are especially interested in outliers -
network components small in D but large in S, which represent tightly clustered network
modules relative to their size. We define the modularity score λ of a subnetwork using
a linear scaling model λ = α log2(S) − log2(D) − β, where α and β are estimated using
linear fitting. With our data, we obtain α = 0.13 and β = 2.2. We select the top 60%
of networks (S ≥ 4) ranked by λ scores, removing those networks having D ≤ 0.34,
and merging heavily overlapping networks. This procedure resulted in 162 second-order
clusters comprising 224 connected network modules, with size ranging from 4 to 64 edges.
175 (78%) modules are statistically significantly functionally homogenous based on the
GeneOntology Biological Process annotation (hypergeometric test p-value < 0.01). The
most predominant functional categories are cell cycle, cell division, cell proliferation,
response to stress, immune response and cell adhesion consistent with known pathological
mechanisms of cancer.
One main feature of our approach is that it can simultaneously discover network
modules and the types of cancer in which the modules are activated. Figure 4.4a shows
a module that is activated in most of the cancer datasets. The genes of the module
are mostly involved in cell division and genetic stability, representing a cell proliferation
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Figure 4.3 The linear relationship between network size S and cluster diameter D. Each
dot in the figure corresponds to a connected network of size ≥ 4. The line is fitted using
networks with size ≥ 10.
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signature, a key feature of cancer. Figure 4.4c shows a network module which tends
to be activated in only solid tumors. The genes of the module are mostly involved in
cell adhesion and organogenesis, which is specific to solid tumor versus blood cancers or
neoplastic cell lines. In the next section, we will detail two network modules which are
activated predominately in breast cancer data sets.
4.2.3 Network modules in the breast cancer cluster
Our analysis resulted in a second-order cluster containing two connected network modules
that tend to be more active in all seven breast tumor datasets relative to the rest of the
datasets. The average correlation of these modules in breast tumor and other cancer
datasets are 0.49 and 0.23 respectively (the t-test of co-expressions between breast tumor
and the rest of cancer datasets gives a p-value of 1.56× 10−95).
4.2.3.1 A tumor suppressor network related to PDGF superfamily
signaling
The module in Figure 4.5a contains 52 genes. Most of them are extracellular or mem-
brane proteins, and 23 genes have previously been found to be involved in breast cancer.
Following are examples of genes in the breast tumor suppressor modules that known to
related to breast cancer : connective tissue growth factor (CTGF) is over-expressed in
breast cancer cell lines with increased metastatic activity [KSS+03]; Fibulin 1 (FBLN1) is
implicated in immune response against breast cancer [PAF+03], and one of its splice vari-
ants is over-expressed in breast [BMM+05]; the cysteine-rich secreted protein (SPARC)
plays a crucial role in tumor development in breast cancer [WDJB+05]; GAS1 is also found
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Figure 4.4 General cancer and solid tumor network modules. (A) A network module
that tend to activate in most of cancer datasets, consisting 24 genes and 28 edges. Average
correlation across all data sets is 0.42. Most of genes in the module are related to cell
division and genetic stability.(B) Another network module that is activated in most of
cancer datasets, consisting 9 genes and 9 edges. The module is located in the same second
order cluster as the one in figure 2a. Its average correlation across all datasets is 0.39.
Most of genes in the module are related to nucleobase, nucleoside, nucleotide and nucleic
acid metabolism. (C) Left : a network that tends to be activated only in solid tumor
datasets. Right, the co-expression heatmap of the edges across datasets. Six datasets
are not shown in the heatmap due to lack of valid co-expression estimations. Average
correlation in solid tumor datasets and other datasets are 0.61 and 0.17, respectively.
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to be induced in apoptotic mammary gland cells [SBB+05]; Cysteine-rich angiogenic in-
ducer 61 (CYR61) is involved in the proliferation, cell survival, and Taxol resistance of
breast cancer [MVM+04]; finally, in the case of a hub gene LRP1 (low density lipoprotein
receptor-related protein 1), the T allele of the C766T polymorphism is associated with
an increased risk of breast cancer development [BJZˇ+03].
Among the 52 genes, 16 are involved in cell adhesion (p-value 7.4×10−11 ), and 14 are
involved cell-cell signalling (p-value 7.9× 10−6 ), suggesting a role in tumor invasiveness
of the module [RLS+04].
General cancer and solid tumor network modules Most interestingly, we found one
main function of this network module appears to be tumor suppression via the inhibi-
tion of PDGF superfamily signaling. A hub gene with high degree of this module is the
gene PDGF receptor-like (PDGFRL) (degree 11). While its precise biological function
is not known, PDGFRL encodes a 375aa product with significant sequence similarity to
the extracellular domain of PDGFR. Indeed, mutations in PDGFRL have been found
in individual cancer samples [KSU+97, LOT+99, ALG+02, KLK+03]. PDGFRL is lo-
cated in chromosome 8p22-8p21.3, where multiple studies have suggested the existence
of a putative breast cancer tumor suppressor gene [YKL+96, SWF+00, RASB+03]. Re-
cently, an in-depth study of the region using microcell-mediated chromosome transfer
found that indeed PDGFRL expression is decreased in the majority of breast cancer
cells [SKW+06]. Many genes in this network module have been found to be involved
in PDGF superfamily signaling. For example, Cysteine-rich protein (SPARC) binds to
PDGF-AB and PDGF-BB dimers, inhibiting the binding of these growth factors to their
cell surface receptors [RLIA+92] and inhibiting PDGF-induced vascular smooth muscle
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Figure 4.5 Coordinated breast tumor network modules. (A) A breast tumor network
module that involved in PDGF signalling. Genes in round shape have promoter regions
that are predicted to be bound by transcription factor ZNF148. (B) A breast tumor net-
work module related to inflammatory response, located in the same second-order cluster
as the one in Figure 3a. Genes in round shape have promoter regions that are predicted
to be bound by transcription factor POU2F1.
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proliferation [MFK+02]. Also, connective tissue growth factor (CTGF) has structural
similarities with PDGF [KMK+05]. Recently, two new PDGF ligands were discovered
that have a N-terminal complement subcomponent C1R/C1S, UEGf, BMP1 (CUB) do-
main [UK05]. Interestingly both C1R and C1S are members of this network module.
Also, LRP1 is a physiological modulator of the PDGF signaling pathway [TMAH05]. In
total, we found direct Pubmed literature support for 19 out of the 52 member genes to
be involved in (or related to) the PDGF-superfamily signalling. Furthermore, it is known
that zinc finger protein (ZNF148) binds to the PDGFR [DBSS+05] gene promoter.
We screened the promoter regions of the 52 member genes, and found that the binding
sites of ZNF148 are significantly enriched (hypergeometric p-value 0.016). In addition,
it has been reported that PDGFR positively regulates collagen production (for exam-
ple [CRH+07, ZBC+06]). Our module showed the breast tumor specific co-expression
between PDGFRL and collagens COL3A1, COL5A2 and COL6A3. Many of the above
evidences support the hypothesis that PDGFRL has an agonistic function to PDGFR
signaling.
Although abundant evidence suggests the individual involvement of many of these
genes in tumor suppression, their coordinated function has never been elucidated. Here
by adopting a network perspective, we have identified their interrelationships and a gene
(PDGFRL) that may play a central role in this tumor suppressor network.
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4.2.3.2 A network module related to inflammatory response
Another identified breast cancer-specific network module (Figure 4.5b) may be involved
in the coordination of the inflammatory response to cancer pathology. This network con-
sists of 5 genes: tumor necrosis factor receptor superfamily member 1B (TNFRSF1B);
vascular cell adhesion molecule 1 (VCAM1); leukocyte-associated immunoglobulin-like re-
ceptor 1 (LAIR1); and Cathepsin L1 (CSTL). They are arranged around the macrophage-
associated antigen (CD163). Several lines of evidence have implicated these genes indi-
vidually in breast cancer, for example: increased plasma levels of VCAM1 is associated
with advanced breast cancer [SGC+06]; genetic variation in TNFRSF1B may predict the
late onset of breast carcinoma, and relapse and death for patients with breast carcinoma
[MBBAC05]; finally, the breast cancer cell line exhibiting the highest in vitro invasiveness
also expressed the highest amount of CTSL1 splice variant L-A3 [CKSL06].
Most of the genes of this module are related to tumor necrosis factor (TNF), an
inflammatory cytokine. It has been reported that activation of rat CD163 on peritoneal
macrophages induces the production of pro-inflammatory mediators including TNF
[PFD+06]; TNF directly interacts with TNFRSF1B [MERS96] and is a mediator of TNF
function in the mouse ovary [GRP+07]. Finally, transcription of VCAM1 in endothelial
cells can be induced by TNF [NRT+95].
A transcription factor, octamer-binding transcription factor-1 (POU2F1, also known
as Oct-1) has been predicted to bind promoter region of VCAM1, LAIR1 and CTSL
(hypergeometric p-value 0.012). The binding of POU2F1 to VCAM1 promoter is indeed
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supported by the literature [SRJ+98,SOG+03,OHB+02]. Also, POU2F1 has been found
to bind SP3 [LLC+03], which is reported to activate the transcription of CSTL [SR04].
The tight and coordinated expression of the genes in this network module reveals
an induced inflammatory response that may be important in breast tumor progression
[Cou02].
4.2.4 Identification of pathway coordination beyond co-expression
A major advantage of second-order clustering is that it can identify functionally related
genes beyond co-expression, as illustrated in Figure 4.1b. We elaborate on this point in
this section. To allow readers to easily assess the magnitude of the correlation, only in
this section we use the Pearson correlation to measure the co-expression level.
Based on the definition of second-order clustering, connected network components
within the same second-order cluster show coordinated activities, which implies their
functional relevance. In the example of the two modules in the general cancer cluster in
Figure 4.4a and 2b, each module may play different roles in the regulation of specific
biological processes – cell division and nucleic acid metabolism, respectively; the latter
is clearly required for cell division. Given the fact that these processes belong to the
same second-order cluster, they may represent facets of the same underlying neoplastic
process. However, member genes of the two modules exhibit distinct expression patterns:
The average Pearson correlation between genes of the two modules is only 0.13.
As another example, the two breast cancer modules described in last section are also
related. Indeed, the collaboration of PDGF signalling and TNF have long been known to
be required for tissue repairing [OMF04], and their abnormal expression play important
75
but partially defined roles in breast tumor development and progression [CMI+06]. On
the other hand, member genes of the two modules exhibit relatively distinct expression
patterns. For example, two hub genes of modules, PDGFRL and CD163, also show very
weak expression similarities across all seven breast cancer datasets: the average Pearson
correlation between these two genes is only 0.24.
Besides the above examples, we found coordinated modules within the majority of
identified second-order clusters. Overall, from the total 162 second-order clusters, 25%
give rise to more than one connected network module. To estimate the amount of cross
module co-expression within second-order clusters, for each second order cluster, we first
determined the active cancer datasets, in which the average Pearson correlation of gene
pairs in the cluster is greater than 0.5. For 72% of those module pairs within the same
second-order cluster, the average gene pairwise Pearson correlation between modules in
the active datasets is less than 0.5 (normalized Percentage Bend correlation approximately
< 0.35), and for 30% module pairs the cross-module average gene pairwise Pearson cor-
relation is less than 0.3 (normalized Percentage Bend correlation approximately < 0.19).
Furthermore, even genes in the same network module are not necessarily highly co-
expressed when the module is active, despite their high degree of functional homogeneity,
as discussed previously. We found that in 32 of 224 (14 %) modules, the average pairwise
Pearson correlation of any two genes in the module is < 0.5 in the corresponding active
datasets. Such modules could therefore easily be overlooked by traditional clustering
methods.
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4.3 Discussion
The rapid accumulation of microarray data provides unprecedented opportunities to study
the molecular mechanisms underlying disease pathogenesis and progression. Although
many studies utilized multiple microarray datasets to derive consistent lists of genes
specific for (subtypes of) cancer [RBR+02, RYS+04, KCYCGK+04], little attention has
been paid to derive genetic networks characterizing different types of cancer. Segal et al.
[SFKR04] used predefined biologically meaningful gene sets including known biological
pathways, and have successfully identified activated or repressed biological modules in a
wide variety of neoplastic conditions. The approach, however, relies on the knowledge of
pre-defined biological modules and has limited use in the discovery of novel association
between genes. A recent study by Choi et al. [CYYK05] compared the two co-expression
networks summarized from 10 tumor and normal datasets, respectively, and have identi-
fied functional differences between normal growth and cancer in terms of gene coexpres-
sion changes in broad areas of physiology. However, due to the multifaceted nature of
cancer, interactions in such a derived summary network may not be simultaneously active
in individual datasets, i.e. specific cancer conditions.
In this study, we propose an unsupervised method that integrates both co-expression
dynamics and network topology information to characterize cancer (subtype) specific
network modules. The identified modules, such as modules activated across all can-
cer subtypes or only in solid tumors, are novel, but consistent with known molecular
mechanisms. Importantly, we have discovered a potential tumor suppressor network par-
ticularly active in breast tumors, and provide compelling evidence that the hub gene
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PDGFRL is a true tumor suppressor gene. Compared to commonly used differential or
co-expression analysis, our approach has the following advantages: (1) our unsupervised
approach simultaneously discovers network modules and the conditions (e.g. cancer sub-
types) in which they are activated, thus providing new insights into the complex cellular
mechanisms that characterize cancer and cancer subtypes. (2) Compared to existing
approaches [CYYK05, LCL+06, CBGB04, SKFW03, BTS+00] which can only identify
densely connected network modules based solely on network topology information, our
approach incorporating co-expression dynamics information (second-order similarity) can
extract more diverse types of modules regardless of network density. It is known that
many biological pathways do not necessarily form densely connected modules. (3) Our
approach can reveal coordination of pathways beyond co-expression. (4) Our method can
be applied to any types of molecular networks beyond co-expression network, when data
of multiple networks under different conditions are available.
In the current framework, the selection of biologically meaningful modules still need
certain amount of manual intervention from biology expert. We are looking for more
systematic ways for module selection, especially by putting the framework into the context
of network statistics to improve the robustness. For example, although the scaling model
we constructed is based on direct observation of the distribution of network properties
S and D, their log-linear relationship suggests that it should be straightforward to make
use of the exponential random graph models that have been used in recent years to
study statistical aspects of networks [CSW05]. In essence, such models linearly combine
network properties and assign the probability of observed networks as the exponential of
such linear combinations. Integrating this work with the exponential family probabilistic
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models may provide both better estimation of the coefficients in the linear scaling model
and more accurate selection of network modules via hypothesis testing. We intend to
explore this direction in future work.
The choice of datasets depends on the research question. Ideally there should be a
balanced and sufficient sampling of different phenotypes (in particular different tissues
for this cancer study). Particularly, a paired Wilcoxon test between cancer and normal
samples of the same tissue would significantly eliminate the amount of tissue-specific co-
expressions. However, due to the limited amount and the heterogeneity of existing data
it is currently impractical to achieve this goal. Using a weighted sampling scheme could
potentially bypass the imbalance effects. We aim to investigate this strategy, and use
statistical models of the correlation values to determine the weighting factors.
4.4 Methods
4.4.1 Datasets
We curated 32 cancer and 23 non-cancer human gene expression datasets mainly from the
Stanford Microarray Database (SMD) and Gene Expression Omnibus (GEO) databases,
each containing more than 15 microarrays, on either Affymetrix or cDNA platforms. In
each dataset, if there are multiple probes that correspond to the same gene, we choose the
one that contains the least amount of missing values. For datasets containing absolute
expression measurements, we convert all values ≤ 10 to 10, then perform a base 2 log
transform. Estimation of Pairwise gene co-expression We used Percentage Bend Correla-
tion [Wil05] (with β = 0.05) to obtain a robust correlation estimate. Percentage Bend
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Correlation first detects outliers in expression values of each gene then reduces the effects
of those outliers in the correlation calculation. Only gene pairs with a large number of
valid samples m ≥ 15 are used to calculate correlation. To make the correlation estimates
comparable across different datasets of variable sample sizes and among different gene
pairs of different amount of missing expression measures within the same dataset, we
performed Fisher’s z-transform [And] to reduce sample size effect. Given a correlation
estimate r and sample size n, the Fisher’s Z scores (divided by its theoretical standard
deviation) is calculated as z =
√
n−3
2 log (
1+r
1−r ), which theoretically has an asymptotically
standard normal distribution. Note that sample size n may be different from gene pair to
gene pair due to missing values, and from dataset to dataset. In reality, we observed that
the distributions of the z-score are still different from dataset to dataset: we therefore
normalized z-scores to enforce the standard normal distribution. After that, standardized
correlations r′ are obtained by inverting the z-score with a fixed n of 30.
4.4.2 Select differentially co-expressed gene pairs
We define a gene pair to be differentially co-expressed between cancer and non-cancer if
it satisfies the following two criteria: (1) their expression correlation in cancer datasets
is sufficiently strong (can be either positively or negatively high). This is done by
setting threshold for average summed square of correlations in cancer datasets. i.e,√
1
c
∑
k (r
(k)
i )
2 < 0.35 for the gene pair i, where there are c valid correlation estima-
tions (c = 32 if there are no missing values) and k is dataset index corresponding to all
valid correlation estimations; and (2) the Wilcoxon ranksum test of correlations between
cancer and non-cancer datasets gives a p-value ≤ 0.01.
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4.4.3 Identify conditionally activated network module candidates
We hierarchically clustered the differentially co-expressed gene pairs based on their ex-
pression correlation profiles using the CLUSTER program [dHINM04] with complete
linkage and Euclidean distance. The Euclidean distance is averaged to provide a simple
estimation given the existence of missing correlations (due to the missing value problem).
di,j =
√
1
c
∑
k (r
(k)
i − r(k)j ) where r(k)i and r(k)j are the correlations of gene pairs i and j in
the dataset k, respectively, and c is number of valid correlations. In the hierarchical tree,
each leaf node represents a gene pair, and each inner node corresponds to a second-order
cluster of gene pairs (edges) which may comprise zero, one, or more connected network
components. In cases where the size of the differential network is too big to be processed
using hierarchical clustering (HC), the gene pairs were first separated using k-means clus-
tering then processed the smaller clusters separately by hierarchical clustering. As for our
experience, the biologically meaningful modules normally contain less than a few hundred
edges, thus k-means clustering will keep most of modules intact.
4.4.4 Gene ontology function and transcription factor enrichment of
modules
The functional enrichment analysis is done by the hypergeometric test on genes. We
selected 419 Gene Ontology (GO) functions (i.e. biological process terms) which are
4 levels below the root in the GO hierarchy. Each gene may be directly or indirectly
associated with some of these functions. A set of genes will be considered to have a
enriched function when (1) the functional homogeneity modeled by the hypergeometric
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distribution [WHD+02] is significant at a significance level 0.01 and (2) there are at least
2 genes in the set are associated with the function.
4.4.5 Identification of transcription factor binding
10kb upstream sequences for each gene were obtained from NCBI Gene database. Af-
ter applying RepeatMasker [SHG04], we used the MATCH program of TRANSFAC
[MFG+03] (version 9.2) to scan the sequences for the presence of transcription factor
binding sites based on position weight matrices. We used vertebrate-specific matrices,
and chose cut-offs to minimize the sum of false positives and false negatives. We kept
only the top 3,000 hits per matrix, sorted by the matrix similarity score. Altogether we
obtained 349,178 predicted transcription factor target relationships of 180 transcription
factors. A hypergeometric test was performed for each network module to search for
over-represented transcription factor binding sites.
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